Advertisement
Screener

Palvella Therapeutics, Inc. (PVLA) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Palvella Therapeutics, Inc. Stock-Based Compensation

Palvella Therapeutics, Inc. (PVLA) reported Stock-Based Compensation of $8.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-04

  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.16M, a 259.73% increase year-over-year.
  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.38M, a 208.59% increase year-over-year.
  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.08M, a 677.61% increase year-over-year.
  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.79M, a 799.50% increase year-over-year.
  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.40M, a 671.20% increase from fiscal 2024.
  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $830.00K, a 37.65% increase from fiscal 2023.
  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $603.00K, a 86.30% decline from fiscal 2022.
  • Palvella Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $4.40M, a 15.59% decline from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 3 month as first filedShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 6 month as first filedShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 9 month as first filedShare-based Payment Arrangement, Noncash Expense 12 monthShare-based Payment Arrangement, Noncash Expense 12 month as first filed
2026-06-30$5.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$8.53M
10-Q · filed 2026-08-04
$10.62M
derived: sum of 3 quarters · filed 2026-08-04
$12.40M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$3.38M
10-Q · filed 2026-05-07
$5.46M
derived: sum of 2 quarters · filed 2026-05-07
$7.25M
derived: sum of 3 quarters · filed 2026-05-07
$8.68M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$2.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$3.87M
derived: sum of 2 quarters · filed 2026-03-31
$5.31M
derived: sum of 3 quarters · filed 2026-08-04
$6.40M
10-K · filed 2026-03-31
2025-09-30$1.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$3.22M
derived: sum of 2 quarters · filed 2026-08-04
$4.32M
10-Q · filed 2025-11-12
$4.58M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$1.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$2.53M
10-Q · filed 2026-08-04
$2.79M
derived: sum of 3 quarters · filed 2026-08-04
$2.99M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$1.09M
10-Q · filed 2026-05-07
$1.36M
derived: sum of 2 quarters · filed 2026-05-07
$1.56M
derived: sum of 3 quarters · filed 2026-05-07
$1.78M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$268.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$467.00K
derived: sum of 2 quarters · filed 2026-03-31
$684.00K
derived: sum of 3 quarters · filed 2026-03-31
$830.00K
10-K · filed 2026-03-31
2024-09-30$199.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$416.00K
derived: sum of 2 quarters · filed 2025-11-12
$562.00K
10-Q · filed 2025-11-12
$1.22M
10-Q · filed 2024-11-13
-$1.73M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$217.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$363.00K
10-Q · filed 2025-08-14
$893.00K
10-Q · filed 2024-08-14
-$1.93M
derived: sum of 3 quarters · filed 2025-08-14
-$966.00K
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$146.00K
10-Q · filed 2025-05-15
$472.00K
10-Q · filed 2024-05-15
-$2.15M
derived: sum of 2 quarters · filed 2025-05-15
-$1.18M
derived: sum of 3 quarters · filed 2025-05-15
-$135.00K
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$2.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-$1.33M
derived: sum of 2 quarters · filed 2025-03-31
-$281.00K
derived: sum of 3 quarters · filed 2025-03-31
$603.00K
10-K · filed 2025-03-31
$3.35M
10-K · filed 2024-03-29
2023-09-30$966.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
$2.01M
derived: sum of 2 quarters · filed 2024-11-13
$2.90M
10-Q · filed 2024-11-13
$3.85M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$1.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$1.93M
10-Q · filed 2024-08-14
$2.88M
derived: sum of 3 quarters · filed 2024-08-14
$3.85M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$884.00K
10-Q · filed 2024-05-15
$1.83M
derived: sum of 2 quarters · filed 2024-05-15
$2.81M
derived: sum of 3 quarters · filed 2024-05-15
$4.11M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$949.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$1.92M
derived: sum of 2 quarters · filed 2024-03-29
$3.22M
derived: sum of 3 quarters · filed 2024-03-29
$4.40M
10-K · filed 2024-03-29
2022-09-30$974.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$2.27M
derived: sum of 2 quarters · filed 2023-11-14
$3.45M
10-Q · filed 2023-11-14
$4.77M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$1.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$2.48M
10-Q · filed 2023-08-10
$3.80M
derived: sum of 3 quarters · filed 2023-08-10
$5.17M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$1.18M
10-Q · filed 2023-05-11
$2.50M
derived: sum of 2 quarters · filed 2023-05-11
$3.87M
derived: sum of 3 quarters · filed 2023-05-11
$5.19M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$1.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$2.69M
derived: sum of 2 quarters · filed 2023-03-31
$4.02M
derived: sum of 3 quarters · filed 2023-03-31
$5.21M
10-K · filed 2023-03-31
2021-09-30$1.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04
$2.70M
derived: sum of 2 quarters · filed 2022-11-04
$3.90M
10-Q · filed 2022-11-04
$5.07M
derived: sum of 4 quarters · filed 2022-11-04
2021-06-30$1.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$2.52M
10-Q · filed 2022-08-04
$3.70M
derived: sum of 3 quarters · filed 2022-08-04
$5.09M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$1.20M
10-Q · filed 2022-05-11
$2.37M
derived: sum of 2 quarters · filed 2022-05-11
$3.77M
derived: sum of 3 quarters · filed 2022-05-11
$5.01M
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02
$2.57M
derived: sum of 2 quarters · filed 2022-03-02
$3.81M
derived: sum of 3 quarters · filed 2022-03-02
$5.09M
10-K · filed 2022-03-02
2020-09-30$1.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02
$2.63M
derived: sum of 2 quarters · filed 2021-11-02
$3.92M
10-Q · filed 2021-11-02
$5.03M
derived: sum of 4 quarters · filed 2021-11-02
2020-06-30$1.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$2.52M
10-Q · filed 2021-08-05
$3.63M
derived: sum of 3 quarters · filed 2021-08-05
$5.15M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$1.28M
10-Q · filed 2021-05-17
$2.40M
derived: sum of 2 quarters · filed 2021-05-17
$3.92M
derived: sum of 3 quarters · filed 2021-05-17
$5.37M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$1.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
$2.63M
derived: sum of 2 quarters · filed 2021-03-31
$4.08M
derived: sum of 3 quarters · filed 2021-03-31
$5.37M
10-K · filed 2021-03-31
2019-09-30$1.52M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04
$2.97M
derived: sum of 2 quarters · filed 2020-11-04
$4.26M
10-Q · filed 2020-11-04
$5.54M
derived: sum of 4 quarters · filed 2020-11-04
2019-06-30$1.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$2.74M
10-Q · filed 2020-08-10
$4.02M
derived: sum of 3 quarters · filed 2020-08-10
$5.33M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$1.29M
10-Q · filed 2020-05-11
$2.57M
derived: sum of 2 quarters · filed 2020-05-11
$3.88M
derived: sum of 3 quarters · filed 2020-05-11
$5.23M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$1.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13
$2.59M
derived: sum of 2 quarters · filed 2020-03-13
$3.94M
derived: sum of 3 quarters · filed 2020-03-13
$4.94M
10-K · filed 2020-03-13
2018-09-30$1.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$2.66M
derived: sum of 2 quarters · filed 2019-11-12
$3.67M
10-Q · filed 2019-11-12
$4.75M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$1.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$2.35M
10-Q · filed 2019-08-09
$3.44M
derived: sum of 3 quarters · filed 2019-08-09
$4.09M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$1.00M
10-Q · filed 2019-05-10
$2.09M
derived: sum of 2 quarters · filed 2019-05-10
$2.74M
derived: sum of 3 quarters · filed 2019-05-10
$3.30M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31$1.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$1.73M
derived: sum of 2 quarters · filed 2019-03-18
$2.29M
derived: sum of 3 quarters · filed 2019-03-18
$3.05M
10-K · filed 2019-03-18
2017-09-30$650.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$1.21M
derived: sum of 2 quarters · filed 2018-11-07
$1.96M
10-Q · filed 2018-11-07
$1.96M
10-Q · filed 2017-11-13
$2.44M
derived: sum of 4 quarters · filed 2018-11-07
2017-06-30$560.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$1.31M
10-Q · filed 2018-08-09
$1.31M
10-Q · filed 2017-08-11
$1.79M
derived: sum of 3 quarters · filed 2018-08-09
$2.24M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$752.00K
10-Q · filed 2018-05-10
$752.19K
10-Q · filed 2017-05-15
$1.23M
derived: sum of 2 quarters · filed 2018-05-10
$1.68M
derived: sum of 3 quarters · filed 2018-05-10
$2.29M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$478.66K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$924.77K
derived: sum of 2 quarters · filed 2018-03-15
$1.54M
derived: sum of 3 quarters · filed 2018-03-15
$1.91M
10-K · filed 2018-03-15
$1.91M
10-K · filed 2017-03-30
2016-09-30$446.11K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13
$1.06M
derived: sum of 2 quarters · filed 2017-11-13
$1.43M
10-Q · filed 2017-11-13
$1.77M
derived: sum of 4 quarters · filed 2017-11-13
2016-06-30$611.85K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
$980.23K
10-Q · filed 2017-08-11
$1.32M
derived: sum of 3 quarters · filed 2017-08-11
$1.66M
derived: sum of 4 quarters · filed 2017-08-11
2016-03-31$368.38K
10-Q · filed 2017-05-15
$709.85K
derived: sum of 2 quarters · filed 2017-05-15
$1.05M
derived: sum of 3 quarters · filed 2017-05-15
$1.32M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$341.47K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30
$679.26K
derived: sum of 2 quarters · filed 2017-03-30
$947.30K
derived: sum of 3 quarters · filed 2017-03-30
$1.16M
10-K · filed 2017-03-30
2015-09-30$337.79K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
$605.83K
derived: sum of 2 quarters · filed 2016-11-10
$823.16K
10-Q · filed 2016-11-10
2015-06-30$268.04K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11
$485.37K
10-Q · filed 2016-08-11
2015-03-31$217.34K
10-Q · filed 2016-05-12
2014-12-31$571.38K
10-K · filed 2016-03-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Generate Biomedicines, Inc. (GENB)United States$2.052B
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12